How I knew when to start backing Novo Nordisk’s biggest rival instead
The Danish firm’s complacency is its undoing in the weight-loss drug war
Add BT as a preferred source
THE folks in Danish drugmaker Novo Nordisk’s orbit seem awfully easy to catch off-guard. When its then chief executive officer Lars Fruergaard Jorgensen was ousted in May, you could have knocked industry analysts over with a feather. Jorgensen himself reportedly had not seen his own sacking coming.
Last week, the beleaguered pharmaceutical giant raised yet more eyebrows with news of its massive board overhaul – all six of its independent directors, as well as its board chair, are to step down, following a disagreement with its controlling shareholder over the firm’s future.
I was surprised, too – surprised that this corporate spring-cleaning hadn’t happened sooner.
TRENDING NOW
DBS, OCBC and UOB shares hit all-time highs as sentiment improves
Targeted credit relief: Vietnam steers funding to Vingroup, Sun Group, Masterise megaprojects
E-commerce job cuts signal S-E Asia’s shift from scaling to deeper user engagement
Employers want AI-fluent employees. Hiring them is the challenge
